Use of complementary and alternative therapies by patients with eye diseases: a hospital-based cross-sectional study from Palestine.
Alternative medicine
CAT
Eye diseases
Palestine
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
04 Jan 2021
04 Jan 2021
Historique:
received:
30
07
2020
accepted:
14
12
2020
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
4
9
2021
Statut:
epublish
Résumé
Generally, complementary and alternative therapies (CAT) are accepted methods of treatment by patients with various types of conditions. Their use is becoming especially prevalent among patients with eye problems even in developed countries. Thus, we aimed to determine the pattern of use of CAT in this patient population, to identify the patient characteristics associated with the use of CAT, and to assess the types of CAT used. A descriptive, cross-sectional study was conducted in Palestine at An-Najah National University Hospital between the time periods of October 2019 to May 2020, using questionnaire-based face to face interviews. Data were collected through convenience sampling. Patients responded to the questionnaire, which was focused on information adapted from previous research in this area, covering socio-demographic and clinical characteristics, types of CAT, source of information, and side effects on CAT use. A total of 86 patients were interviewed for our study. Over two thirds, 67% reported using CAT for the specific purpose of improving their eye condition, and about one third (29.1%) received more than one therapy. The most common therapies reported were duea' (i.e. supplication) (47.1%) and herbal therapies (24.1%). It was shown that patients with bilateral involvement of their eyes were almost twice more likely to describe using CAT than patients with unilateral eye pathology (p = 0.006). Also, patients who underwent surgery as their route of treatment were significantly less likely to use CAT (p = 0.043). Most of our study participants mentioned a non-physician source as their source of information regarding CAT with family members being the most frequently mentioned (30.2%) followed by the internet (25.6%) and friends (19.8%). The prevalence of CAT use among patients with eye disease is somewhat high in our study population. Because CAT may trigger adverse reactions, influence the progression of the disease, and interfere with conventional treatment, the ophthalmologist should frequently be asked patients with such diagnostics regarding the use of these therapies. Further work is required to analyze the mechanisms of action and to establish realistic guidelines for the use of these modalities.
Sections du résumé
BACKGROUND
BACKGROUND
Generally, complementary and alternative therapies (CAT) are accepted methods of treatment by patients with various types of conditions. Their use is becoming especially prevalent among patients with eye problems even in developed countries. Thus, we aimed to determine the pattern of use of CAT in this patient population, to identify the patient characteristics associated with the use of CAT, and to assess the types of CAT used.
METHODS
METHODS
A descriptive, cross-sectional study was conducted in Palestine at An-Najah National University Hospital between the time periods of October 2019 to May 2020, using questionnaire-based face to face interviews. Data were collected through convenience sampling. Patients responded to the questionnaire, which was focused on information adapted from previous research in this area, covering socio-demographic and clinical characteristics, types of CAT, source of information, and side effects on CAT use.
RESULTS
RESULTS
A total of 86 patients were interviewed for our study. Over two thirds, 67% reported using CAT for the specific purpose of improving their eye condition, and about one third (29.1%) received more than one therapy. The most common therapies reported were duea' (i.e. supplication) (47.1%) and herbal therapies (24.1%). It was shown that patients with bilateral involvement of their eyes were almost twice more likely to describe using CAT than patients with unilateral eye pathology (p = 0.006). Also, patients who underwent surgery as their route of treatment were significantly less likely to use CAT (p = 0.043). Most of our study participants mentioned a non-physician source as their source of information regarding CAT with family members being the most frequently mentioned (30.2%) followed by the internet (25.6%) and friends (19.8%).
CONCLUSIONS
CONCLUSIONS
The prevalence of CAT use among patients with eye disease is somewhat high in our study population. Because CAT may trigger adverse reactions, influence the progression of the disease, and interfere with conventional treatment, the ophthalmologist should frequently be asked patients with such diagnostics regarding the use of these therapies. Further work is required to analyze the mechanisms of action and to establish realistic guidelines for the use of these modalities.
Identifiants
pubmed: 33397355
doi: 10.1186/s12906-020-03188-9
pii: 10.1186/s12906-020-03188-9
pmc: PMC7784325
doi:
Substances chimiques
Plant Extracts
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Références
Ophthalmology. 2008 Mar;115(3):435-439.e2
pubmed: 17900696
J Ethnopharmacol. 2013 Oct 28;150(1):79-84
pubmed: 23933314
BMC Complement Altern Med. 2017 Aug 29;17(1):429
pubmed: 28851351
Pharmazie. 2001 Apr;56(4):343-7
pubmed: 11338678
Br J Ophthalmol. 2001 Jul;85(7):767-8
pubmed: 11423443
J Altern Complement Med. 2007 Mar;13(2):263-9
pubmed: 17388770
Surv Ophthalmol. 2001 Jul-Aug;46(1):43-55
pubmed: 11525790
Curr Opin Allergy Clin Immunol. 2003 Oct;3(5):395-9
pubmed: 14501441
BMC Complement Altern Med. 2016 Jul 11;16:204
pubmed: 27400742
J Ethnopharmacol. 2016 Jul 1;187:104-22
pubmed: 27125594
J Glaucoma. 2014 Sep;23(7):430-4
pubmed: 23429615
J Postgrad Med. 2007 Apr-Jun;53(2):96-101
pubmed: 17495374
Contemp Nurse. 2009 Aug;33(1):41-9
pubmed: 19715494
J Asthma. 2004 Apr;41(2):131-9
pubmed: 15115165
Br J Cancer. 2004 Jan 26;90(2):408-13
pubmed: 14735185
BMC Complement Med Ther. 2020 Jul 20;20(1):231
pubmed: 32689988
Ocul Immunol Inflamm. 2004 Sep;12(3):203-14
pubmed: 15385195
J Glaucoma. 2012 Feb;21(2):79-82
pubmed: 21173701
J Pain Symptom Manage. 2015 May;49(5):878-84
pubmed: 25499828
Cont Lens Anterior Eye. 2017 Dec;40(6):360-366
pubmed: 28919243
Complement Ther Clin Pract. 2015 May;21(2):84-93
pubmed: 25900613
Ger Med Sci. 2015 Jun 23;13:Doc05
pubmed: 26161049
Complement Ther Clin Pract. 2011 Nov;17(4):235-40
pubmed: 21982140
Cochrane Database Syst Rev. 2013 May 31;(5):CD006030
pubmed: 23728656
BMC Complement Altern Med. 2019 Apr 2;19(1):78
pubmed: 30940118
J Complement Integr Med. 2014 Jun;11(2):139-45
pubmed: 24698828
Complement Ther Med. 2013 Feb;21(1):58-64
pubmed: 23374206
Complement Ther Clin Pract. 2013 Nov;19(4):256-63
pubmed: 24199984
Eur J Ophthalmol. 2020 Oct 2;:1120672120960337
pubmed: 33008269
Klin Monbl Augenheilkd. 2017 May;234(5):686-696
pubmed: 27459518
Forsch Komplementmed. 2012;19 Suppl 2:18-28
pubmed: 23883941
Curr Eye Res. 2011 Sep;36(9):787-96
pubmed: 21812661
Ophthalmology. 2002 Mar;109(3):438-43
pubmed: 11874744
Evid Based Complement Alternat Med. 2010 Dec;7(4):419-24
pubmed: 18955344
Evid Based Complement Alternat Med. 2020 May 10;2020:4520769
pubmed: 32454859
Complement Ther Clin Pract. 2012 Feb;18(1):16-21
pubmed: 22196568
Int J Pharm Pract. 2010 Aug;18(4):242-4
pubmed: 20636677
Curr Eye Res. 2013 Dec;38(12):1283-7
pubmed: 23972126
Evid Based Complement Alternat Med. 2013;2013:549174
pubmed: 23843879
Oxid Med Cell Longev. 2019 Feb 12;2019:9783429
pubmed: 30891116
Nutrients. 2020 Oct 16;12(10):
pubmed: 33081127